Figure 2From: Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot studyComparison of the overall survival between the two groups separated by the CA19-9 cutoff value of 338.45 U/mL. A significant difference in survival was revealed by the log-rank test (P = 0.009).Back to article page